Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?

Journal of Psychopharmacology

Volumn 28, Issue 7, 2014, Pages 665-670

  Koola, Maju M ^a   Tsapakis, Evangelia M ^b   Wright, Padraig ^c   Smith, Shubulade ^b   Kerwin, Robert W ^b   Nugent, Katie L ^d   Aitchison, Katherine J ^b  

^a SHEPPARD PRATT HEALTH SYSTEM   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Takeda Global Research and Development Centre Europe   (United Kingdom)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

antipsychotic; Cytochrome P450; genotype; Parkinsonism; tardive dyskinesia

Indexed keywords

CHLORPROMAZINE; CYTOCHROME P450 2D6; DNA; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; PIMOZIDE; THIORIDAZINE; ZUCLOPENTHIXOL DECANOATE;

ADULT; ALLELE; ARTICLE; CAUCASIAN; CYP2D6 GENE; DSM-III-R; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT DURATION; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDY; ENGLAND; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; ODDS RATIO; PHARMACOGENETIC VARIANT; PHARMACOGENETICS; PHENOTYPE; PSYCHOLOGY; STATISTICAL MODEL; TIME FACTOR;

ADULT; ANTIPSYCHOTIC AGENTS; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2D6; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; LONDON; MALE; MIDDLE AGED; ODDS RATIO; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; PHENOTYPE; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TARDIVE DYSKINESIA; TIME FACTORS;

EID: 84902583340     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114523861     Document Type: Article

References (47)

1. Aitchison K, Datla K, Rooprai H, et al. Regional distribution of clomipramine and desmethylclomipramine in rat brain and peripheral organs on chronic clomipramine administration. J Psychopharmacol. 2010 ; 24: 1261-1268
2. Aitchison KJ, Gonzalez FJ, Quattrochi LC, et al. Identification of novel polymorphisms in the 5' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance. Pharmacogenetics. 2000 ; 10: 695-704
3. Aitchison KJ, Munro J, Wright P, et al. Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. Br J Clin Pharmacol. 1999 ; 48: 388-394
4. 1987) DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition-Revised. Washington, DC: American Psychiatric Press, Inc. Washington, DC: American Psychiatric Press, Inc ; 1987 :
5. Bakker PR, Van Harten PN, Van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9gly polymorphism in the Drd3 gene: A meta analysis. Schizophr Res. 2006 ; 83: 185-192
6. Basile VS, Ozdemir V, Masellis M, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia. Mol Psychiatry. 2000 ; 5: 410-417
7. De Leon J, Susce MT, Pan RM, et al. Polymorphic variations in Gstm1, Gstt1, Pgp, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol. 2005 ; 25: 448-456
8. Ebstein RP, Macciardi F, Heresco-Levi U, et al. Evidence for an association between the dopamine D3 receptor gene Drd3 and schizophrenia. Hum Hered. 1997 ; 47: 6-16
9. Fang J, Baker GB, Silverstone PH, et al. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol. 1997 ; 17: 227-233
10. Fang J, Yu PH, Gorrod JW, et al. Inhibition of monoamine oxidases by haloperidol and its metabolites: Pharmacological implications for the chemotherapy of schizophrenia. Psychopharmacology (Berl). 1995 ; 118: 206-212
11. Fu Y, Fan CH, Deng HH, et al. Association of CYP2A6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin. 2006 ; 27: 328-332
12. Ghannoum MA, Mukherjee PK, Jurevic RJ, et al. Metabolomics reveals differential levels of oral metabolites in HIV-infected patients: toward novel diagnostic targets. OMICS. 2013 ; 17: 5-15
13. Huezo-Diaz P, Perroud N, Spencer EP, et al. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol. 2012 ; 26: 398-407
14. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005 ; 5: 6-13
15. Jaanson P, Marandi T, Kiivet RA, et al. Maintenance therapy with zuclopenthixol decanoate: Associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berl). 2002 ; 162: 67-73
16. Jeste DV, Kelsoe JR. Schizophrenia, tardive dyskinesia, and a D3 receptor gene variant: A new twist on dyskinesias?. Mol Psychiatry. 1997 ; 2: 86-88
17. Jeste DV, Wyatt RJ. Changing epidemiology of tardive dyskinesia: An overview. Am J Psychiatry. 1981 ; 138: 297-309
18. Kane JM. Tardive dyskinesia in affective disorders. J Clin Psychiatry. 1999 ; 60: S43 - S47
19. Kane JM, Smith JM. Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982 ; 39: 473-481
20. Kane JM, Woerner M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull. 1986 ; 22: 254-258
21. Kapitany T, Meszaros K, Lenzinger E, et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res. 1998 ; 32: 101-106
22. Keers R, Uher R, Gupta B, et al. Stressful life events, cognitive symptoms of depression and response to antidepressants in Gendep. J Affect Disord. 2010 ; 127: 337-342
23. Liou YJ, Wang YC, Bai YM, et al. Cytochrome P-450 2D6*10 C188t polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in chinese schizophrenic patients. Neuropsychobiology. 2004 ; 49: 167-173
24. Llerena A, Dahl ML, Ekqvist B, et al. Genetic factors in the metabolism of haloperidol. Clin Neuropharmacol. 1992 ; 15: 84A - 85A
25. Morgan ET, Sewer MB, Iber H, et al. Physiological and pathophysiological regulation of cytochrome P450. Drug Metab Dispos. 1998 ; 26: 1232-1240
26. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 1993 ; 50: 723-733
27. Muscettola G, Barbato G, Pampallona S, et al. Extrapyramidal syndromes in neuroleptic-treated patients: Prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol. 1999 ; 19: 203-208
28. Nikoloff D, Shim JC, Fairchild M, et al. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J. 2002 ; 2: 400-407
29. Owens DG, Johnstone EC, Frith CD. Spontaneous involuntary disorders of movement: Their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry. 1982 ; 39: 452-461
30. Patsopoulos NA, Ntzani EE, Zintzaras E, et al. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: A meta-analysis. Pharmacogenet Genomics. 2005 ; 15: 151-158
31. Plesnicar BK, Zalar B, Breskvar K, et al. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol. 2006 ; 20: 829-833
32. Quinn J, Meagher D, Murphy P, et al. Vulnerability to involuntary movements over a lifetime trajectory of schizophrenia approaches 100%, in association with executive (frontal) dysfunction. Schizophr Res. 2001 ; 49: 79-87
33. AmpliChip CYP450 Test for In Vitro Diagnostic Use. Branchburg, New Jersey: Roche Molecular Systems ; 2005 :
34. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet. 1997 ; 60: 284-295
35. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982 ; 39: 486-487
36. Schulze TG, Schumacher J, Muller DJ, et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet. 2001 ; 105: 498-501
37. Segman R, Neeman T, Heresco-Levy U, et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry. 1999 ; 4: 247-253
38. Segman RH, Heresco-Levy U, Yakir A, et al. Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biol Psychiatry. 2002 ; 51: 261-263
39. Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 ; 27: 1078-1084
40. Smith JM, Baldessarini RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry. 1980 ; 37: 1368-1373
41. Spitzer RL, Williams JBW, Gibbon M, First Michael B 1990 ) Structured Clinical Interview for DSM-III-R, Patient Edition/Non-patient Edition,(SCID-P/SCID-NP), Washington, DC: American Psychiatric Press, Inc. Washington, DC: American Psychiatric Press, Inc ; 1990 :
42. Tsapakis EM, Meagher D, Quinn J, et al. A genetic association study of the CYP1A2 C164A polymorphism and tardive dyskinesia. Schizophrenia Research. 2002 ; 53: 75
43. Waddington JL, O'Callaghan E, Buckley P, et al. Tardive dyskinesia in schizophrenia. relationship to minor physical anomalies, frontal lobe dysfunction and cerebral structure on magnetic resonance imaging. Br J Psychiatry. 1995 ; 167: 41-44
44. Webster DD. Critical analysis of the disability in Parkinson's disease. Mod Treat. 1968 ; 5: 257-282
45. Williams J, Spurlock G, Holmans P, et al. A meta-analysis and transmission disequilibrium study of association between the dopamine D3 receptor gene and schizophrenia. Mol Psychiatry. 1998 ; 3: 141-149
46. Woerner MG, Alvir JM, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors. Am J Psychiatry. 1998 ; 155: 1521-1528
47. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2d6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004 ; 369: 23-37